Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.72 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22566723 | 0.91 | IKZF2 (0.65) | CRBNIKZF2 | |
| SCHEMBL24942108 | 0.89 | CRBN (0.63) | CRBNIKZF2 | |
| SCHEMBL27139685 | 0.88 | CRBN (0.67) | CRBN | |
| SCHEMBL19503629 | 0.87 | CRBN (0.72) | CRBNIKZF2 | |
| SCHEMBL20234563 | 0.87 | CRBN (0.66) | CRBN | |
| SCHEMBL30007020 | 0.87 | CRBN (0.66) | CRBN | |
| SCHEMBL27090524 | 0.87 | CRBN (0.66) | CRBN | |
| SCHEMBL21760318 | 0.86 | CRBN (0.74) | CRBN | |
| SCHEMBL1413525 | 0.86 | CRBN (0.57) | CRBNIKZF2 | |
| SCHEMBL19503639 | 0.84 | CRBN (0.69) | CRBNIKZF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807977-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BIOVENTURES, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190135801-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BIOVENTURES, LLC | 2019-05-09 | — | — | US | disclosed |
| US-20190054097-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | BIOVENTURES, LLC | 2019-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135801-A1 | COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF | BCL2, BAX, BCL2L1 | CRBN 520/4885IKZF2 556/4885 |
| US-10807977-B2 | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof | BCL2, BAX, BCL2L1 | CRBN 520/4885IKZF2 556/4885 |
| US-20190054097-A1 | COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF | TP53, MCL1, LIMS1 | CRBN 1187/4885IKZF2 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.